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Improvement of growth and food utilization by human recombinant
growth hormone in uremia. We compared growth rate, food conversion
ratio and morphology of the growth zone in female Sprague-Dawley rats
with subtotal nephrectomy or sham operation. Both groups were either
given vehicle or 1.4 lU/day recombinant human growth hormone (OH)
by s.c. osmotic minipump, or 2.5 IU twice daily intraperitoneally for 14
or 20 days, respectively. Compared to uremic rats infused with vehicle,
infusion of GH significantly (P < 0.01) improved growth; that is, it
increased gain of weight ( 27.0 7.7 g vs. 11.6 4.9 g) and length (z
1.8 0.3cm vs. 1.12 0.44cm) in ad libitum fed uremic rats. This was
accompanied by increased food utilization ratio (0.146 vs. 0.065 g
weight gain per g food intake). A similar increment of growth and food
utilization ratio was also observed in OH versus solvent infused
controls, either pained as for the uremic animals or fed ad libitum.
Despite administration of OH, growth was not completely restored to
normal in uremic animals. Circulating immunoreactive IGF I was not
significantly increased by OH infusion in either uremic animals or
controls. Histological analyses of the proximal tibia showed increased
rate of longitudinal growth, as evaluated by tetracyclin-labeling, and
increased volumetric density of primary spongiosa with unchanged
width of primary spongiosa trabecules when OH was infused in uremic
animals. The data suggest that growth impairment in the uremic rat is
partially responsive to OH, and this is not accompanied by an increase
of circulating IOF I. Therapeutic trials with recombinant OH in uremic
children appear justified.
The genesis of impaired growth in uremic children is multi-
factorial, but hormonal factors apparently play a major role U].
Levels of growth hormone (GH) under basal conditions are
elevated in renal failure [2, 3], similarly to what is found in
malnutrition. Such elevated levels may in part be due to
diminished catabolism and excretion by the kidney [4]. Further
complexity of interpretation is introduced by the pulsatile
character of GH secretion and by recently recognized discrep-
ancies between radioimmunoassay and radioreceptorassay [51.
Abnormalities of the regulation of GH secretion, such as in
response to changed blood glucose concentration or thyrotropin
releasing factor (TRF), have also been observed in uremia [2].
The actions of GH on growth are generally thought to be
mediated by somatomedins/insulin-like growth factors (IGF)
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which share considerable amino acid sequence homology with
insulin. Discrepant results on serum levels of somatomedins/
IGF have been reported in uremic subjects [6, 7] and animals
[8]. The issue is rendered complex by apparent changes in the
relative contributions of IGF I and IGF II to total IGF levels in
renal failure [9, 10]. Based on indirect evidence, Phillips and
Kopple [3] recently suggested increased activity of a low
molecular weight inhibitor of somatomedinllGF in renal failure.
The paradoxical presence of elevated OH levels despite
diminished growth raises the possibility of endorgan resistance.
In uremia, impaired responsiveness is well known for hormones
like parathyroid hormone [11] or insulin [121. Since recombi-
nant GH has recently become available in relatively large
amounts for use in humans, we felt it important to examine
whether growth failure in uremia could be reversed, at least in
part, by OH at dosages which would be available for clinical
use. For this purpose, longitudinal growth, weight gain, food
conversion ratio and histology of the growth zone in the upper
tibia were examined. We compared nephrectomized Sprague-
Dawley rats and their sham operated controls, which received
either pharmacological doses of GH or vehicle by subcutaneous
administration using osmotic minipumps.
Methods
Experimental animals
Female Sprague-Dawley rats (Fa. Ivanovas, Kisslegg/Allgäu,
Switzerland) weighing 120 g were used for the experiment. Prior
to the study, animals had free access to food (Altromin C 1000
diet; Altromin Co., Lage/Lippe, Switzerland) and deionized
water. The animals were kept in single cages with constant
room temperature (24°C) and humidity (70%) on a 12 hour onIl2
hour off light cycle. The diet contained 13,800 kJ/kg; 0.95% Ca;
0.8% P; 500 lU/kg vitamin D3; 18% protein (wt/wt). Animals
were subjected to two-stage nephrectomy (NX) as described
before [13]. The second kidney was removed and uremia was
induced when the animals had a median body weight of 166 g.
Controls (CO) were sham operated (renal decapsulation). In the
pilot series, animals had free access to food and deionized
water. In the definite experiments, both groups with free access
to food and water, and groups pained as previously described
[13] were examined. In the pilot study (Fig. 1) duration of
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Pairfed Ad libitum
control control Ad libitum
NX vehicle vehicle NX GH Pairfed control vehicle control GH(N = 7) (N = 7) (N = 7) GH (N = 7) (N = 8) (N = 8)
Cumulativefoodintakeg 174±4 174±4 184±6 184±7 225 5 229±5
Initial length cm 36.0 0.31 35.9 0.25 35.7 0.28 35,8 0.28 35.8 0.13 35.8 0.28
Final length cm 37.1 0.33 37.4 0.28 37.5 0.40 37.7 0.25 38.3 0.19 38.9 0.20
A length cm 1.12 0.16 1.45 0.08 1.80 0.lla 1.94 0.15a 2.48 0.09 3.00 0.19"
Initial weight g 166 2 170 3 162 3 169 3 166 1 164 2
Final weight g 177 2 185 2 189 6 205 6 203 1 213 4
A weight g 11.6 1.8 14.7 2.3 27.0 2.9a 36.0 39a 36.9 1.1 48.7 2.1k
Weight gain 0.065 0.03 0.083 0.01 0.146 0.Ola 0.190 0.Ola 0.164 0.01 0.212 o.Ola
Food intake
Muscle weight dry mg 247 9 263 8 268 8' 292 8 288 4 323 9
Liver weight dry mg 2.62 0.09 2.70 0.11 2.79 0.09 2.87 0.07 3.55 0.08 3.90 0.2
Heart weight dry mg 141 3 131 2 166 3 152 a 143 3 156 4
a P < 0.01 difference between GH and solvent for uremic animals or control animals
bp < 0.05 difference between GH and solvent for uremic animals or control animals
uremia was 20 days. In the definite experiments (Tables 1, 2 and
morphological studies) the duration of uremia was 14 days.
Experimental protocol
According to the information from Kabi Co. [14], 0.5 U
human GH extracted from human hypophyses (Cresconnon'),
when administered by daily i.p. injection, failed to affect growth
rate of normal rats [14]. In a preliminary experiment we
confirmed this finding, and, in addition, noted no stimulation of
growth in uremic rats fed ad libitum.
Because of the limited amount of material, a pilot series of
experiments was examined as to whether the highest logistical-
ly-feasible dose affected growth in uremic animals. Eight NX
animals were treated with a high intermittent dose, that is, 2.5
IU recombinant human GH (hGH; Kabi Co., Sweden; Soma-
tonorm' 200 U/mg, dissolved in distilled water) twice daily by
intraperitoneal injection. NX controls with free access to food
and water received vehicle alone. The animals were observed
over 20 days. The results are reported in Figure 1.
In the definite experiment (Tables 1 and 2), 1.4 IU hGH per
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Fig. 1. Effect of 2 x 2.5 lU/day hGH i.p. on growth in subtotally nephrectomized rats. (A) Cumulative gain in length (nose-tail tip, in mm). (B)
Cumulative gain in weight (g). N = 8 animals per group; x SCM. Symbols are: (0 0) vehicle control; (• •) animals with hGH.
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Table 1. Growth in subtotally nephrectomized rats treated with recombinant human GH by osmotic minipumps s.c.
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Table 2. Biochemical data in subtotally nephrectomized rats treated wi th human GH by osmotic minipumps S.C.
Pairfed Ad libitum
Control Pairfed Control Ad libitum
NX vehicle vehicle NX GH Control Gil vehicle Control GH(N=7) (N=7) (N=7) (N=7) (N=8) (N=8)
Creatinine mg/dl 1.01 0.02 0.52 0.02 0.98 0.02 0.54 0.02 0.5 0.01 0.48 0.02
Urea mg/dl 115 3.1 33 1.5 112 6.4 39 2.4 31 3.1 39 2.6
K mmol/ljter 4.4 0.12 4.11 0.19 4.73 0.16 3.63 0.15 4.37 0.33 3.67 0.09
Ca mmol/liter 2.69 0.03 2.5 0.03 2.71 0.05 2.57 0.03 2.55 0.01 2.61 0.03
P mmol/Iiter 2.67 0.10 2.55 0.06 2.67 0.05 2.50 0.05 2.70 0.09 2.45 0.04
Glucose mg/dl 121 3 113 2 119 1 88 7b 118 4 113 2
Protein g/liter 56.7 0.7 54.6 0.3 62.2 0.9 62 l.la 52.2 0.4 58 0.8l
GH ng/ml (RIA; ref. 16) 0.53 0.06 0.31 0.04 >20° >20° 0.32 0.03 >20°
IgF iiU/ml (competitive 612 120 580 42 519 150 562 79 — —
bind, assay)
IgF I ng/ml (RIA; ref. 16) 188 10 207 6 174 4 239 14 168 11 176 10
IgF I ng/ml serum pool 248 163 221 138 175 196
(RIA; ref. 17/18)
CarrierproteinmgEqtJml 0.56 0.18 0.62 0.13 1.83 0.15a 1.98 o.16
a p < 0.01 difference Gil vs. solvent for uremic animals or control animals
"P < 0.05 difference GH vs. solvent for uremic animals or control animals
day was administered by s.c. osmotic minipump (Aizet Co.,
model 2 ML 1) for two weeks (detailed in Spec jfication and
Description of Aizet Osmotic Pump Function, Alza Co., Palo
Alto, California, May 1985).
Control animals received vehicle by s.c. osmotic minipump.
As shown in Table 1, three groups were compared: NX vehicle
with pairfed control vehicle-treated; NX + hGH with pairfed
control + hGH; and ad libitum fed control + vehicle with ad
libitum control + hGH.
Results of one representative series are reported in Tables 1
and 2. The results were confirmed in two further series which
will not be described in detail. The animals of one confirmatory
series were used for histological analysis.
Measurements
All measurements of body weight were performed in non-
fasted animals in the morning. Nose breech and nose tail tip
distances were measured under ether anaesthesia and deep
muscle relaxation as described before [13]. All organs were
weighed before and after desiccation (24 hr; 70°C; desiccant).
Blood was obtained by aortic puncture in non-fasted animals at
the end of the experiment. Serum chemistry was measured with
multichannel Technicon Autoanalyzer (Technicon Instruments,
Tarrytown, New York, USA). Immunoreactive GH was mea-
sured by double antibody RIA in serum of non-fasted animals
using a human GH antibody in a commercial kit (Serono Co.,
Freiburg/Brsg., FRG). For assay of IGF, serum samples were
chromatographed on a Sephadex G50 column (0.5 cm diameter,
20 cm length) in 1.0 M acetic acid (pH 2.3) to dissociate the
IGF-binding protein complex. A competitive protein binding
assay to measure total IGF activity, that is, IGF-I and IGF-II,
was used [15]. An RIA using a specific antiserum directed
against human IGF-I/SmC and '251-IGF-I (iodogene method) as
the tracer was used to quantitate IGF-I alone; IGF-II cross-
reacts less than 3% in this system as has been previously
described [16]. Independently, serum pools of the respective
groups were processed as described [17] and examined with an
RIA [18] using an antiserum against human IGF-I that cross-
reacts with rat IGF-I. The exact cross-reaction was unknown
because no rat IGF was available for standardization. IGF
carrier protein was determined by a radioligand assay employ-
ing '251-IGF-I as the tracer and partially-purified carrier protein
derived from pooled human sera as the standard [15].
Histological measurements in proximal tibia growth zone
Animals were given the fluorescent marker calcein [191 by
single s.c. injection (10 mg) on the days prior the nephrectomy
and prior to sacrifice, respectively.
The proximal tibiae were cut in frontal slices and fixed in 40%
(vol/vol) ethanol at +4°C for 24 hours. After dehydration in a
graded series of ethanol at + 20°C, tissue slices were infiltrated
and embedded in methylmetacrylate. After completion of poly-
merization, 5 m thick sections were cut on a Jung microtome
1140 in frontal planes. Sections were subsequently mounted on
gelatin-coated slides and stained either by the von Kossa
reaction modified by Krutsay or by Toluidine blue 0 [19].
Quantitative morphological estimation of metaphyseal trabecu-
lar volume and surface density (using the von Kossa stained
sections) was performed with the assistance of a Quantimet 720
(Imanco Ltd., Cambridge Instruments, Cambridge, UK) auto-
matic image analyzer [19]. The Toluidine blue 0-sections were
used for morphometric estimations (height of total growth plate,
of proliferating and hypertrophic zones) [20, 21]. In addition,
from each tibia, 10 m sections were mounted unstained for
measurement of growth rates by use of incident light fluores-
cence microscopy [20, 21].
Statistics
Data are given as x SEM. Results were evaluated using
Wilcoxon's test for random samples or paired differences as
appropriate; histological measurements were evaluated using
the t-test.
Results
Effect of 2 x 2.5 lU/day hGH i.p. on growth in subtotally
nephrectomized rats
Ad libitum-fed uremic animals receiving 2 X 2.5 lU/day hGH
by intraperitoneal injection in the pilot study continuously
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gained length (Fig. 1A) and weight (Fig. IB) at a faster rate than
vehicle injected uremic animals. Nose breech distance (data not
given) increased in parallel with nose tail distance. There was
no significant difference of cumulative food consumption (hGH
184 9.9 g; solvent 181 7.6 g). Treatment with hGH did not
significantly affect renal function in this series, since elevation
of serum creatinine and decrease of endogenous creatinine
clearance was similar in the two groups (hGH: serum creatinine
1.62 0.07 mg/dl; CCr 72.6 8.3 pJ/min/l00 g; vehicle: serum
creatinine 1.66 0.08 mg/dl; CCr 70.9 5.2 d/minIl00 g).
Effect of 1.4 IU hGH by osmotic minipumps s.c. on growth in
subtotally nephrectomized rats
Tables 1 and 2 give the result of three paired groups of the
definite experiment, One group of vehicle treated NX animals
was pait-fed with vehicle treated, sham-operated control ani-
mals. This protocol provided an examination of the effects of
uremia on growth under conditions of controlled food intake.
One group of hGH treated NX animals was pairfed with hGH
treated sham-operated, control animals. The effects of hGH on
uremic animals can be evaluated by comparing NX vehicle
treated animals with NX hGH treated animals. Comparison of
NX + hGH and pairfed controls + hGH provided an evaluation
of whether the effects of hGH are different in uremic animals
and control animals under conditions of controlled food intake.
Finally, one group of ad libitum fed, vehicle-injected sham-
operated control animals was compared with, but not pairfed
to, hGH-treated sham-operated, ad libitum-fed control animals.
This protocol permitted an evaluation of whether hGH had an
intrinsic effect on food intake.
Uremic animals had considerably less food consumption than
ad libitum fed control animals. The adequacy of the pairfeeding
protocols is documented by similar food intake in uremic
animals and their pairfed controls. In ad libitum fed control
animals, hGH had no significant effect on food consumption.
NX animals with vehicle grew 1.12 cm per two weeks while NX
animals with hGH grew 1.80 cm. The two groups were not
pairfed but cumulative food intake and initial length were
virtually identical. A similar increment in longitudinal growth
was seen in sham operated controls: 1.94cm versus 1.45 cm. A
stimulatory effect on longitudinal growth, though somewhat
less in magnitude, was also seen in control animals with
unrestricted access to food. Stimulation of longitudinal growth
in uremic animals and sham operated controls was accompa-
nied by similar stimulation of weight gain. Food utilization
ratio, that is, weight gain pet unit weight of food consumed, was
significantly increased by administration of hGH in both uremic
and sham operated controls, and was even noted in control
animals with unrestricted access to food. The dry weight of one
skeletal muscle, m. triceps surae, was higher in both hGH-
treated uremic animals and controls than in the respective
vehicle-treated groups. The same was true for liver and heart
dry weight. The increment in organ weight went in parallel with
the increment of body weight, since the organ weight/body
weight ratio was not significantly altered.
Uremic animals with and without hGH were comparble with
respect to serum creatinine and serum urea levels. hGH had no
consistent effect on serum urea, electrolytes and glucose.
Immunoreactive GH levels were significantly increased, doc-
umenting efficacy of the delivery system.
Fig. 2. Microradiographs of frontal sections through the proximal
tibiae. (A.) Sham-operated control animal. (B.) Sham-operated control
animal receiving growth hormone (GH) (C.) Uremia induced by subto-
tal nephrectomy. Both groups B and C exhibit an increase in volume
density of the primary spongiosa within the proximal metaphysis of
approximately 25% to 30% (compared to the control group A). (D.)
Uremic animal treated with GH. Compared to the control A, the
volume density of the proximal metaphyseal spongiosa is increased by
approximately 60%. (X5.5: 1).
Total IGF, measured by competitive binding protein assay
[15] showed no significant difference between solvent and
hGH-treated groups. This finding was confirmed by a RIA for
IGF with virtually no cross-reactivity with IGF II, using an
antibody raised against human IGF I. This result was further
validated by independently measuring serum pools of the re-
spective groups, measured with the procedure of Zapf et al [17,
181, which again failed to show a difference between solvent and
hGH-treated groups. In contrast, total IGF binding capacity for
IGF rose significantly in hGH-treated uremic and non-uremic
animals, confirming previous observations in rats [221 and
humans [23].
Histological evaluation of the growth apparatus of the
proximal tibia
Microradiographic analyses (Fig. 2) showed widening of the
radiolucent growth zone and increased density of metaphysis in
sham operated rats treated with hGH 1.4 lU/day s.c. by osmotic
minipumps. The width of the growth zone was already greater
in solvent-treated uremic animals and further increased after
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Fig. 3. Light micrographs of proximal tibia! growth plates. Thick (5 tm) sections, stained with Toluidine blue 0. (A.) Sham-operated control
animal. (13.) Sham-operated control animal receiving GH. The growth plate of this group (B) is increased in height by approximately 15 to 20%
(compared to A). (C.) Uremia induced by subtotal nephrectomy. Growth plate height is only slightly increased relative to that of the control animals
(A). (D.) Uremic animal treated with GH. Growth plate height is increased by approximately 35 to 40% (compared with control group A). Such
increase is mainly attributable to an increase in the number of hypertrophic chondrocytes within cell columns, the number of proliferating
chondrocytes per column remaining unaltered. A similar pattern of change is observed in B. (x 200: 1).
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Table 3. Histological evaluation of the growth apparatus of the proximal tibia
Width of zone
Width of of Volumetric
Treatment(N = 5 per
group)
Rate of
growth
% of
control
growth
zone
piday
% of
control
hypertrophic
cartilage
% of
control density oftrabeculesa
%
% of
control
trabecular
diameter
j.
% of
controlpJday day
(A)NX+STH 204 7.36 116 346 26 138 172 18.4 177 28,2 2.50 164 23.2 1.82 81.1
(B)CO+STH 217 8.86 124 292 10 117 124 9.87 128 22.2 1.16 129 30.0 1.06 104
(C)NX+vehicle 169 8.14 96 216 16 104 111 19.7 114 21.5 0.34 125 27.4 1.63 95
(D)CO+vehicle 176 5.5 100 250 8 100 97 7.18 100 17.2 1.31 100 28.8 1.14 100
Significance (1-test)
A vs. B 0.2 0.05 0.023 0.05 0.01
A vs. C 0.01 0.0125 0.025 0.025 0.1
A vs. D 0.01 0.005 0.0025 0.0025 0.025
B vs. C 0.0025 0.1 0.29 0.3 0.15
B vs. D 0.0025 0.01 0.03 0.0125 0.25
C vs. D 0.3 0.35 0.25 0.01 0.25
a Trabecules of metaphyseal spongiosa
administration of hGH. Histological analysis, as shown in
Figure 3, documented that in hGH-treated control animals (but
not in hGH-treated uremic animals) the height of proliferating
cartilage was increased (data not given). As shown in Table 3,
the increase in width of the growth zone in hGH-treated NX
animals and controls, respectively, was mainly due to an
increased height of the zone of hypertrophic cartilage. This
resulted from the persistence of more cartilage cells (Fig. 3).
Furthermore, confirming the microradiographic findings (Fig.
2), more trabecules of unchanged width were noted in the
metaphyseal spongiosa. In uremic animals, increased numbers
of osteoclasts and increased numbers of abnormally broad
osteoid seams were encountered; this was not changed by
administration of hGH.
Increased width of growth cartilage in hGH-treated sham-
operated controls, and more so in hUH-treated uremic animals,
was paralleled by increased growth rate measured by fluores-
cence labeling.
Discussion
The present study documents that in uremic rats human GH
increases growth velocity, weight gain and food utilization
ratio. This was complemented by histological findings in the
proximal tibia which confirmed increased width of the zone of
hypertrophic cartilage and increased rate of longitudinal growth.
This finding extends previous observations from this laboratory
[24] that radiothymidine incorporation into growth cartilage is
low in uremia and increases in response to GH. The stimulatory
effect on growth persisted throughout the experiment. Conse-
quently, the action of GH is not explained merely as an acute
reversal of postoperative stress-induced catabolism. At the
chosen dose, human GH improved growth, but failed to com-
pletely normalize growth velocity and weight gain in uremic
animals. Although a complete dose-response relationship in
uremic animals was not established, we noted that 0.5 IU hGH
per day failed to affect growth in uremic animals, as previously
shown in non-uremic controls [14]. The dose used for uremic
animals in the present study was equivalent to the dose which
had been shown to be maximally effective in normal, female
Sprague-Dawley rats [14]. In assessing the biological action of
GH one must also consider potential prolongation of GH half
life secondary to loss of catabolic sites in the kidney [41. It is
unknown whether continuous administration by osmotic mini-
pumps is appropriate for a hormone which under normal
circumstances is secreted in a pulsatile fashion, but intermittent
i.p. injection of GH gave at least quantitatively similar results
(Fig. 1 vs. Table 1). Food consumption was not substantially
higher in GH-treated animals; yet, food utilization ratio, that is,
weight gain per gram food consumed as an index of anabolism,
was consistently higher with administration of GH. The ratio
did not normalize in uremic rats. Despite prolonged half life of
GH [4], it must also be considered that binding of GH to liver
membranes was found to be decreased in rats with renal
insufficiency [251; it has also been reported that the concentra-
tion of a hepatogenic growth-hormone-dependent plasma pro-
tein is lower in uremic patients despite elevated immunoreac-
tive GH levels [26]. These observations, taken together with
our observations that high doses of GH partially reverse growth
failure of uremia, are compatible with the notion of GH hypo-
responsiveness in uremia. Alternatively, other factors unrelated
to GH may importantly contribute to growth impairment in
renal failure.
Several factors may influence the action of GH. In the above
study, female rats were chosen because it had been shown that
GH has more marked effects on non-uremic female rats [14].
Because GH may affect GFR, both serum creatinine (pilot and
definite experiments) and endogenous creatnine clearance (pilot
experiment) were monitored. Cc. was not examined in the
definite experiments, since urine collection in metabolic cages
is stressful and might have altered growth zone morphology and
growth hormone measurements. There was no significant dif-
ference of serum creatinine or endogenous creatinine clearance,
suggesting that the effect of hGH is not an artefact secondary to
improved GFR.
GH is known to cause salt retention in several species. This
cannot explain, however, our observations for the following
reasons: 1) dry weight of organs was increased, particularly of
skeletal muscle; 2) longitudinal growth also increased; 3) spe-
cific metabolic effects of GH are indicated by increased food
conversion ratio.
In the past it has been widely assumed that the growth-
promoting effect of GH is mediated via circulating insulin-like
factors, such as somatomedins [271. Recent results suggest that
the issue is more complex. Local injection of pharmacological
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concentrations of GH in vivo into the cartilage growth plate
results in accelerated longitudinal bone growth [28], a finding
which has been interpreted to mean that it is not the increase in
the plasma concentration of IGF that causes such stimulation.
Furthermore, growth hormone stimulates proliferation of cul-
tured chondrocytes after addition in vitro [291. When pharma-
cological concentrations of growth hormone are added in vitro
to embryonic rat tibia cultures for seven days, an increase in
alkaline phosphatase levels is seen, and this is associated with
release of IGF I-like factors into the culture medium [30].
However, in a preliminary study it has recently been reported
[31] that growth hormone has a mitogenie action on chicken
osteoblasts without demonstrable increase of IGF I activity
[31]. Further complexity is suggested by the observation of
Ernst and Froesch [32] that in osteoblast clones maintained in
serum-free medium, the stimulatory effect of maximal concen-
trations of growth hormone plus IGF I was greater than with
each hormone alone. Direct action of growth hormone on
growth cartilage target cells, induction by growth hormone of
local mediators, or restoration of the responsiveness of carti-
lage cells to the action of IGF by high growth hormone
concentrations may explain the unexpected finding that no
increase of IGF concentration was observed in GH-treated
uremic or control rats. The failure of IGF to rise was confirmed
in three independent assays in two different laboratories. A
speculative but intriguing explanation for the stimulatory effect
of GH on growth despite no change in circulating IGF would be
that hepatic IGF I production is already maximal at normal GH
levels. If GH modulates growth by altering IGH I responsive-
ness of growth cartilage, a possibility compatible with the above
in vitro studies [32], high doses of GH may overcome a
hypothetical decrease of GH responsiveness in uremia.
Apart from the above growth effects, the biological efficacy of
administered GH is also documented by the GH-induced rise in
IGF binding capacity, confirming previous observations in
animals [22] and humans [23].
Because of the above encouraging results and the recent
availability of recombinant human GH in virtually unlimited
amounts, we propose that the effects of hGH on growth rate of
children with terminal uremia should be examined in controlled
clinical trials. Studies to this end in dialyzed children have been
initiated in our institution. Since the effect of hGH on glomer-
ular function of children with preterminal uremia have not been
defined, and may potentially be unfavorable in the long run,
caution is required in children with residual renal function.
Acknowledgments
The RIA using a specific antiserum directed against human
IGF-I/Sm C and '251-IGF-I was a gift from Drs van Wyk and
Underwood, Chapel Hill, North Carolina, USA. We thank
cand. med. F. Biundo and M. Haag for technical assistance and
Ms. Stelz for typing the manuscript. The help of Dr. Steinkamp
(Kabi Co.) in providing the recombinant GH and background
information is gratefully acknowledged.
Portions of this study were presented at the 23rd Congress of
the EDTA-ERA, Budapest, Hungary, June 29th—July 3rd, 1986.
Reprint requests to Professor Dr. Otto Mehis, Department of Pedi-
atrics, University of Heidelberg, Im Neuenheimer Feld 150, D-6900
Heidelberg, Federal Republic of Germany.
References
1. MEHLS 0, RITz E, GILL! G, KREUSSER W: Growth in renal failure.
Nephron 2 1:237—246, 1978
2. LIM VS, KATHPALIA SC, HENRIQUEZ C: Endocrine abnormalities
associated with chronic renal failure. Med Clin NAm 62:1341—1344,
1978
3. PHILLIPS LS, KOPPLE JD: Circulating somatomedin activity and
sulfate levels in adults with normal and impaired kidney function.
Metabolism 30:1091—1095, 1981
4. JOHNSON J, MAACK T: Renal extraction, filtration, absorption and
catabolism of growth hormone. Am J Physiol 233:F185—Fl89, 1977
5. FRAZER T, GAVIN JR, DAUGHADAY WH, HILLMAN RE, WELDON
VV: Growth hormone—dependent growth failure. J Pediatr 101:12—
15, 1982
6. SPENCER EM, UTHNE KO, ARNOLD WC: Growth impairment with
elevated somatomedin levels in children with chronic renal insuffi-
ciency. Acta Endocrinol 91:36—48, 1979
7. TAKANO K, HALL K, KASTRUP KW, HIZUKA N, SHIZUME K,
KAwAI K, AKIM0T0 M, TAKUMA T, SUGINO N: Serum somato-
medin A in chronic renal failure. J Clin Endocrinol Metab 48:371—
376, 1979
8. SCHALCH DS, BURSTEIN PJ, TEWEL SJ, DIzNlN B, EMLER CA:
The effect of renal impairment on growth in the rat: Relationship to
malnutrition and serum somatoniedin levels. Endocrinol 108:1683—
1689, 1981
9. BAXTER RC, BROWN AS, TURTLE JR: Radioimmunoassay for
somatomedin C: comparison with radioreceptor assay in patients
with growth hormone disorder, hypothyroidism and renal failure.
Gun Chem 28:488—495, 1982
10. GOLDBERG AC, TRIVEDI B, DELMEZ JA, HARTER HD.
DAUGHADAY WH: Uremia reduces serum insulin-like growth factor
I, increases insulin-like growth factor II, and modifies their serum
protein binding. (abstract) J Clin Endocrinol Metab 55:1040, 1982
11. LLACH F, MASSRY SG, SINGER FR, KUROKAWA K, KAYE JH,
COBURN JW: Skeletal resistance of endogenous parathyroid hor-
mone in patients with early renal failure. A possible cause of
secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339—
345, 1975
12. DEFRONZO RA, ROBIN JD, ROWE JW, ANDERS R: Glucose intol-
erance in uremia. Quantification of pancreatic beta cell sensitivity
to glucose and tissue sensity to insulin. J CIin Invest 62:425—435,
1978
13. MEHLS 0, RITZ E, GILLI G, SCHMIDT-GAYK H, KREMPIEN B,
KOURIST B, WESCH H, PRAGER P: Skeletal changes and growth in
experimental uremia. Nephron 18:288—300, 1977
14. EKRARM S, JOHANSSON HE: (Kabi AB, Research Department):
Scientific Report 8199038, 1—89, 1981
15. SCHALCH DS, HEINRICH UE, KOCH JG, JOHNSON Ci, SCHLUETER
Ri: Non-suppressible insulin-like activity (NSILA). I. Develop-
ment of a new sensitive competitive protein-binding assay for
determination of serum levels. J C/in Endocrinol Metab 46:664—
671, 1978
16. HEINRICH U, HARTMANN K, MULLER M, FEHRES J, SCHONBERG
D: Insulin like growth factor and carrier protein serum levels in tall
girls on high dose estrogens. (abstract) Pediatr Res 19:611, 1985
17. ZAPF J, HAURI C, WALDVOGEL M, FROESCH ER: Acute metabolic
effects and half-lives of intravenously administered insulinlike
growth factors I and II in normal and hypophysectomized rats. J
C/in Invest 77:1768—1775, 1986
18. ZAPF J, WALTER H, FROESCH ER: Radioimmunological determina-
tion of insulinlike growth factors I and II in normal subjects and in
patients with growth disorders and extrapancreatic tumor hypogly-
cemia. J C/in Invest 68:1321—1330, 1981
19. SCHENK R, EGGLI P, FLEISCH H, R05INI 5: Quantitative morpho-
metric evaluation of the inhibitory activity of new aminobisphos-
phonates on bone resorption in the rat. Calcif Tiss mt 38:342—349,
1986
20. CRUZ-ORIVE LM, HUNZIKER EB: Stereology for anisotropic cells:
Application to growth cartilage. J Microsc 143:47—80, 1986
21. HUNZIKER EB, SCHENK RK, CRUZ-ORIVE LM: Quantitation of
chondrocyte performance in epiphyseal plates during longitudinal
bone growth. J Bone ft Surgery (Americ Volume) 69A: 162—173,
52 Mehls et a!: Improvement of growth by GH in uremia
1987 press)
22. SCHALCH DS, HEINRICH UE, DRAZNIN B, JOHNSON CJ, MILLER
LL: Role of the liver in regulating somatomedin activity: Hormonal
effects on the synthesis and release of insulin-like growth factor and
its carrier protein by the isolated perfused rat liver. Endocrinol
104:1143—1 151, 1979
23. WHITE RM, NISSLEY SP, MOSES AC, RECHLER MM, JOHNSON-
BAUGH RE: The growth hormone dependence of a somatomedin-
binding protein in human serum. J C/in Endocrinol Metab 53:49—57,
1981
24. KREUSSER W, WEINKAUFF R, MEHLS 0, Rirz E: Effect of para-
thyroid hormone on cAMP content of growth cartilage in experi-
mental uremia. Eur J C/in Invest 12:337—343, 1982
25. FINID0RI 3, POSTEL-VINAY C, KLEINKNECHT C: Lactogenic and
somatotropic binding sites in liver membranes of rats with renal
insufficiency. Endocrinol 106:1960—1965, 1980
26. BERRYSA, SEELIG S: Substantial induction of a new serum protein
by growth hormone; physiochemical and physiological character-
ization. JEndocrinol 115:116.4—1170, 1984
27, DAUGHADAY WH, HALL K, RABEN MS, SALMON WD, VAN DEN
BRANDE JL, VAN WYK JJ: Somatomedin: A proposed designation
for the 'sulfation factor". Nature 235:107—109, 1972
28. IsAKssoN OGP, JANSSON JO, GAUSE JAM: Growth hormone stim-
ulates longitudinal bone growth directly. Science 216:1237—1239,
1982
29. MADSEN K, FRIBERG U, ROOS P. ISAKSS0N 0: Growth hormone
stimulates the proliferation of cultured chondrocytes from rabbit
ear and rat rib growth cartilage. Nature 304:545—547, 1983
30. STRACKE H, SCHULZ A, MOELLER D, ROSSOL S, SCHATZ H: Effect
of growth hormone on osteoblasts and demonstration of somato-
medin-C/IGF I in bone organ culture. Acta Endocrinol 107:16—24,
1984
31. SLOOTWEG MC, VAN BUUL-OFFERS SC, DUURSMA SA: Mitogenic
action of growth hormone on fetal chicken osteoblasts without
production of somatomedins. IXth International Conference on
Calcium Regulating Hormones and Bone Metabolism. Oct 25—Nov
1, 1986, Nice, France, (abstract) p. 329
32. ERNST M, FROESCH ER: Stimulatory effects of human growth
hormone on osteoblastic cells (Ob) in a serum-free culture system.
IXth International Conference on Calcium Regulating Hormones
and Bone Metabolism. Oct 25—Nov 1, 1986, Nice, France, (ab-
stract) p. 311
